摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(methylthio)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide | 866410-80-2

中文名称
——
中文别名
——
英文名称
7-(methylthio)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide
英文别名
7-methylsulfanyl-[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide
7-(methylthio)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide化学式
CAS
866410-80-2
化学式
C7H6N4OS2
mdl
——
分子量
226.283
InChiKey
MHMKMGGRNLSSKB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    135
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED PYRAZOLO-PYRIDINAMINES<br/>[FR] PYRAZOLO-PYRIDINAMINES SUBSTITUÉES
    申请人:BAYER PHARMA AG
    公开号:WO2015004024A1
    公开(公告)日:2015-01-15
    The present invention relates to substituted pyrazolopyridine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及通式I所述和定义的取代吡唑吡啶化合物,涉及制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和复合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防过度增殖和/或血管生成紊乱的疾病,作为唯一药剂或与其他活性成分组合使用。
  • Thiazolopyrimidine Derivative
    申请人:Sugihara Yoshihiro
    公开号:US20080269238A1
    公开(公告)日:2008-10-30
    The present invention provides a compound represented by the following Formula: wherein A is an aryl group or a heteroaryl group, each of which may be substituted; R 1 is a group which is bonded through carbon; R 2 is hydrogen or an aliphatic hydrocarbon group; and X is —NR 3 —, —O—, —S—, —SO—, —SO 2 —, or —CHR 3 — (wherein R 3 is hydrogen or an aliphatic hydrocarbon group), or a salt thereof, or a prodrug thereof, which has growth factor receptor tyrosine kinase inhibitory activity and low toxicity, and is useful for prevention and treatment of cancer, and thus can be sufficiently used as a medicine.
    本发明提供了以下式子所表示的化合物:其中,A是芳基或杂芳基,每个都可以被取代;R1是通过碳键结合的基团;R2是氢或脂肪烃基团;X是-NR3-、-O-、-S-、-SO-、-SO2-或-CHR3-(其中,R3是氢或脂肪烃基团),或其盐或前药。该化合物具有生长因子受体酪氨酸激酶抑制活性和低毒性,并且对于预防和治疗癌症非常有用,因此可以充分用作药物。
  • THIAZOLOPYRIMIDINE DERIVATIVE
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1731523A1
    公开(公告)日:2006-12-13
    The present invention provides a compound represented by the following Formula: wherein A is an aryl group or a heteroaryl group, each of which may be substituted; R1 is a group which is bonded through carbon; R2 is hydrogen or an aliphatic hydrocarbon group; and X is -NR3-, -O-, -S-, -SO-, -SO2-, or -CHR3-(wherein R3 is hydrogen or an aliphatic hydrocarbon group), or a salt thereof, or a prodrug thereof, which has growth factor receptor tyrosine kinase inhibitory activity and low toxicity, and is useful for prevention and treatment of cancer, and thus can be sufficiently used as a medicine.
    本发明提供了由下式表示的化合物: 其中 A 是芳基或杂芳基,每个芳基或杂芳基均可被取代;R1 是通过碳键合的基团;R2 是氢或脂肪族烃基;X为-NR3-、-O-、-S-、-SO-、-SO2-或-CHR3-(其中R3为氢或脂族烃基),或其盐,或其原药,具有生长因子受体酪氨酸激酶抑制活性和低毒性,可用于预防和治疗癌症,因此可充分用作药物。
  • SUBSTITUTED PYRAZOLO-PYRIDINAMINES
    申请人:Bayer Pharma Aktiengesellschaft
    公开号:EP3019505A1
    公开(公告)日:2016-05-18
查看更多

同类化合物

噻唑并[5,4-d]嘧啶-7(4H)-酮 噻唑并[5,4-d]嘧啶-5,7(4H,6H)-二酮 噻唑并[5,4-d]嘧啶-2(1H)-酮 噻唑并[5,4-d]嘧啶,5-氯- 噻唑[5,4-D]嘧啶-2-胺 叔丁基-(7-氯噻唑并[5,4-d]嘧啶-2-基)-胺 [1,3]噻唑并[5,4-D]嘧啶-7-胺 N7-丁基-n2-苯基噻唑并[5,4-d]嘧啶-2,7-二胺 N7-(4-甲氧基苯基)-n2-苯基噻唑并[5,4-d]嘧啶-2,7-二胺 N7-(3-氯苯基)-n2-苯基噻唑并[5,4-d]嘧啶-2,7-二胺 N2-苯基-n7-(3,4,5-三甲氧基苄基)噻唑并[5,4-d]嘧啶-2,7-二胺 N2,N7-二苯基-噻唑并[5,4-d]嘧啶-2,7-二胺 N-(7-氯-2-甲基噻唑并[5,4-D]嘧啶-5-基)新戊酰胺 8-苯胺基-9-硫杂-2,4,7-三氮杂双环[4.3.0]壬-2,7,10-三烯-5-硫酮 7-氯噻唑并[5,4-D]嘧啶 7-氯-N-(邻甲苯基)噻唑并[5,4-D]嘧啶-2-胺 7-氯-5-甲基-[1,3]噻唑并[5,4-d]嘧啶 7-氯-5-(三氟甲基)[1,3]噻唑并[5,4-d]嘧啶 7-氨基-噻唑并[5,4-d]嘧啶-2(1H)-硫酮 7-(甲硫基)噻唑并[5,4-D]嘧啶-2-羧酸甲酯 5-甲硫基-9-硫杂-2,4,7-三氮杂双环[4.3.0]壬-2,4,7,10-四烯 5,7-二氯噻唑并[5,4-D]嘧啶 5,7-二氯-2-甲基-噻唑并[5,4-d]嘧啶 4-(5-氯噻唑并[5,4-D]嘧啶-7-基)吗啉 2-苯胺基[1,3]噻唑并[5,4-d]嘧啶-7-醇 2-苯基噻唑并[5,4-d]嘧啶-7-胺 2-甲基-4H-噻唑并[5,4-d]嘧啶-5,7-二酮 2-乙氧基[1,3]噻唑并[4,5-d]嘧啶-5,7(4H,6H)-二酮 2-(甲基硫代)-噻唑并[5,4-d]嘧啶-7(4H)-酮 2,7-二氯噻唑并[5,4-D]嘧啶 2,5-二氯噻唑并[5,4-d]嘧啶 2,5-二氨基-6H-[1,3]噻唑并[4,5-e]嘧啶-7-酮 1-(7-氯噻唑并[5,4-d]嘧啶-2-基)-1,3-二甲基硫脲 1,3-二苄基-1-(7-氯噻唑并[5,4-d]嘧啶-2-基)硫脲 (7-氯噻唑并[5,4-d]嘧啶-2-基)苯胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)异丙胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-对甲苯-胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-吡啶-3-基-胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-(4-甲氧基苯基)胺 (7-氯噻唑并[5,4-d]嘧啶-2-基)-(2,6-二甲基苯基)胺 (6CI,7CI,8CI,9CI)-噻唑并[5,4-d]嘧啶 4-[7-methyl-4,6-dioxo-2-(3-phenyl-prop-1-ynyl)-6,7-dihydro-4H-1,4l4-dithia-3,5,7-triaza-inden-5-ylmethyl]-benzoic acid 7-Amino-2-methyl-5-hydroxy-thieno<3.2-g>pteridin 7-Amino-3-ethylmercapto-5-hydroxy-2-methyl-thieno<3.2-g>pteridin 2-(6-morpholin-4-yl-4H-[1,3]dithiino[5,4-d]pyrimidin-8-ylamino)-ethanol 2-ethoxycarbonylaminothiazolo[5,4-d]pyrimidine-7(6H)-one 7-chlorothiazolo[5,4-b]pyridine-2-carbonitrile 3-Brom-5-oxo-7-amino-2-(1,2-dihydroxyethyl)-thieno<3.2-g>pteridin 5-amino-2-(cyclohexyl)thiazolo[5,4-d]pyrimidine-7-thiol 5-amino-2-(2-furyl)-thiazolo[5,4-d]pyrimidine-7-thiol